Low doses of a human antibody in mice were effective in repairing damaged myelin, a protective shield for nerves that is destroyed by multiple sclerosis. Scientists at the Mayo Clinic engineered an antibody--rHIgM22--so that it would bind to myelin and brain and spinal cord cells. That antibody triggered remyelination, restoring the protective sheath. This is the first known therapy that acts within the central nervous system. In addition, the scientists said that even at a very high dose, there were no recorded side effects from the treatment.
- here's the report from the Washington Post